Camber offers Q1 recap
New launches emphasize Camber’s continued investment in expanding patient access to high-quality, affordable treatments.
New launches emphasize Camber’s continued investment in expanding patient access to high-quality, affordable treatments.
Investments in health services reflect the view of pharmacy as a clinical touchpoint and loyalty driver.
Expands access to FDA-approved GLP-1 treatment with transparent pricing and integrated support through GoodRx for Weight Loss.
The new innovative packaging is easier to handle, more compact, and designed to improve the patient experience, especially for those with mobility challenges.
Gives plan sponsors much greater pricing visibility and transparency by shifting infusion therapies covered under the medical benefits to the pharmacy benefit.
Katie Scanlon’s appointment to head the business reaffirms a focus on pharmacist-led care.
Aurigene provides AI-enabled integrated drug discovery services supporting Alveus’ research programs in obesity and metabolic disease.
‘Customers and patients will continue to have the same great experience.’
Albertsons’ Q4 results showed continued pressure on its pharmacy, with a $773.8 million opioid-related charge causing a net loss and highlighting reimbursement and pricing issues.
Strong year-over-year sales growth that was driven by core pharmacy prescription growth and sale of GLP-1 drugs.
He succeeds Dean Edney, who served the company for six years and played an important role in strengthening its PR&D capabilities.
Pharmacists completed thousands of comprehensive medication management visits.
Wedell-Wedellsborg led Danish chain Matas into becoming a digital market leader
Awards honor excellence and improvement in overall CMS Medicare Part D Star Ratings and PQA Medication Measures.
The chain is renewing its emphasis on its core pharmacy and retail platform.
The company was the first grocer to enlist in the Make Health Technology Great Again initiative.